<p>Bloodstream infections (BSIs) remain among the most lethal clinical syndromes, driven in large part by diagnostic delays that compel empiric, broad-spectrum antimicrobial therapy and expose patients to avoidable toxicity and resistance selection. Conventional blood culture–based workflows, although diagnostically definitive, are intrinsically slow, often requiring 24–72 h, and are therefore poorly matched to the time-critical demands of sepsis management, where each hour of delayed appropriate therapy measurably increases mortality. In this context, nano-enabled nucleic acid diagnostics represent a promising but largely preclinical strategy for improving analytical sensitivity and turnaround time. This critical translational review examines how engineered nanomaterials spanning plasmonic and magnetic nanoparticles, fluorescent quantum dots, upconversion nanoparticles, and two-dimensional materials synergize with programmable nucleic acid recognizers, including aptamers, CRISPR/Cas effectors, DNAzymes, and conformational probes, to enable rapid, ultrasensitive detection of pathogens and resistance determinants directly from whole blood. Rather than reviewing nanomaterials and nucleic acid probes as separate toolkits, this article focuses on how their co-design at the nano–bio interface enables clinically actionable whole-blood diagnostics. We elucidate how convergence engineering at the nano–bio interface governs signal amplification, background suppression, and assay robustness in complex biological matrices. Particular emphasis is placed on front-end enrichment strategies, optical and magnetic transduction mechanisms, and multiplexed readout architectures that together enable species-level identification and early antimicrobial susceptibility profiling within clinically relevant timeframes, typically ~ 1–6 h in research settings. Beyond analytical performance, we critically assess interconnected translational barriers including batch-to-batch reproducibility, standardization of bioconjugation protocols, antifouling strategies, and evolving regulatory frameworks, which collectively govern the trajectory from laboratory innovation to clinical adoption. At present, direct-from-blood phenotypic antimicrobial susceptibility testing remains technically challenging, and clinical adoption is limited by reproducibility, matrix tolerance, and workflow integration. By integrating mechanistic insight with clinical positioning, this review frames nano-probe diagnostics as promising candidates for next-generation BSI management that may support more timely and precise therapy once analytical robustness, standardization, and clinical validation are achieved.</p>